German Dx Firm Taps N-of-One to Provide Clinical Interpretation for NGS Testing | GenomeWeb

NEW YORK (GenomeWeb) – N-of-One said this week that it has been selected by CeGaT to interpret data from its next-generation sequencing-based oncology tests.

Under the terms of the agreement, N-of-One will analyze data from CeGaT's NGS panel which tests for more than 550 cancer genes. The company's interpretation results will include biological and clinical information about mutations found in the tumor as well as access to potential therapeutic strategies and clinical trials.

Financial and other terms of the deal were not disclosed

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.